Revvity (RVTY)
Health Care · $16.0B market cap · SEC CIK 0000031791
fundamentals score out of 100
Next reports on Oct 26, 2026, before the open, with analysts expecting $1.32 in earnings per share.
The case for RVTY
- Generated $509M of free cash flow in FY2025, 18% of revenue.
- Within 4% of its 52-week high: the trend is up.
- Up 65.6% over the past year.
The case against
- Very expensive at 67.3× earnings. Years of growth are already in the price.
- Revenue has shrunk 5.5% a year over five years.
- Return on equity of only 3%.
- Earnings per share fell 10.8%.
- Stability is weak (31/100): beta 1.11, 4.5 years of cash flow to clear its debt, a 46% swing over the year.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 32 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 14 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 41 |
| Momentumhow the price has behaved lately | 92 |
| Stabilityhow violently it moves, what it owes and what it pays you | 31 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 67.3× |
|---|---|
| Price / book | 1.74× |
| Price / sales | 5.5× |
| Revenue growth (YoY) | +4.0% |
| EPS growth (YoY) | -10.8% |
| Gross margin | 55% |
| Operating margin | 12% |
| Net margin | 8% |
| Return on equity | 3% |
| Debt / equity | 0.44× |
| Current ratio | 1.80 |
| Dividend yield | 0.31% |
| Beta | 1.11 |
| 52-week range | $81.22 – $149.52 |
| Position in that range | 91% of the way up |
| 3-month return | +43.6% |
| 1-year return | +65.6% |
Five years of financials, as filed
Pulled from Revvity's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B |
| Gross profit | — | — | — | $2.0B | $2.4B |
| Operating income | $357M | $347M | $301M | $743M | $1.3B |
| Net income | $241M | $270M | $693M | $569M | $943M |
| Operating cash flow | $583M | $628M | $91.3M | $680M | $1.4B |
| Capital expenditure | $73.5M | $86.6M | $81.4M | $85.6M | $86.0M |
| Total assets | $12.2B | $12.4B | $13.6B | $14.1B | $15.0B |
| Total liabilities | $4.9B | $4.7B | $5.7B | $6.7B | $7.9B |
| Shareholder equity | $7.3B | $7.7B | $7.9B | $7.4B | $7.1B |
| Cash | $920M | $1.2B | $913M | $454M | $603M |
| Long-term debt | $2.6B | $3.2B | $3.2B | $3.9B | $5.0B |
| Free cash flow | $509M | $542M | $9.9M | $594M | $1.3B |
| Gross margin | — | — | — | 60.1% | 63.6% |
| Operating margin | 12.5% | 12.6% | 10.9% | 22.4% | 32.9% |
| Net margin | 8.4% | 9.8% | 25.2% | 17.2% | 24.6% |
| Diluted shares | 117M | 123M | 125M | 126M | 117M |
Share count is essentially flat over 4 years.
What Revvity says it does
Overview We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol "RVTY" and we are a component of the S&P 500 Index. We maintain a website with the address http://www.revvity.com . We are not including the information contained in our website as part of, or incorporating it by reference into, this annual report on Form 10-K. We…
Risk factors RVTY lists in its 10-K
- Fostering a Positive Workplace Culture
- Risks Related to our Business Operations and Industry
- Our growth and profitability are subject to global economic and political conditions, and operational disruptions at our facilities
- If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets
- If we do not compete effectively, our business will be harmed
- If we do not retain our key personnel, our ability to execute our business strategy will be limited
- Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation
- Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets
- Risks Related to our Intellectual Property
- We may not be successful in adequately protecting our intellectual property
- If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage
- Risks Related to Legal, Government and Regulatory Matters
- The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability
- Changes in governmental regulations may reduce demand for our products or increase our expenses